179 related articles for article (PubMed ID: 31445185)
1. Association between Clonal Hematopoiesis and Late Nonrelapse Mortality after Autologous Hematopoietic Cell Transplantation.
Slavin TP; Teh JB; Weitzel JN; Peng K; Wong FL; Qin H; Wang J; Wu X; Mei M; Pillai R; Wang Y; Tsang KK; Pozhitkov A; Krishnan A; Forman SJ; Armenian SH
Biol Blood Marrow Transplant; 2019 Dec; 25(12):2517-2521. PubMed ID: 31445185
[TBL] [Abstract][Full Text] [Related]
2. Hematopoietic Cell Transplantation-Specific Comorbidity Index Predicts Morbidity and Mortality in Autologous Stem Cell Transplantation.
Berro M; Arbelbide JA; Rivas MM; Basquiera AL; Ferini G; Vitriu A; Foncuberta C; Fernandez Escobar N; Requejo A; Milovic V; Yantorno S; Szelagoswki M; Martinez Rolon J; Bentolila G; Garcia JJ; Garcia P; Caeiro G; Castro M; Jaimovich G; Palmer S; Trucco JI; Bet LA; Shaw BE; Kusminsky GD
Biol Blood Marrow Transplant; 2017 Oct; 23(10):1646-1650. PubMed ID: 28669923
[TBL] [Abstract][Full Text] [Related]
3. The clinical implications of clonal hematopoiesis in hematopoietic cell transplantation.
Nawas MT; Schetelig J; Damm F; Levine RL; Perales MA; Giralt SA; VanDenBrink MR; Arcila ME; Zehir A; Papaemmanuil E; Klussmeier A; Schmidt AH; Maiwald S; Bolton KL; Tamari R
Blood Rev; 2021 Mar; 46():100744. PubMed ID: 32896435
[TBL] [Abstract][Full Text] [Related]
4. Physiologic Frailty in Nonelderly Hematopoietic Cell Transplantation Patients: Results From the Bone Marrow Transplant Survivor Study.
Arora M; Sun CL; Ness KK; Teh JB; Wu J; Francisco L; Armenian SH; Schad A; Namdar G; Bosworth A; Kuo L; Weisdorf DJ; Forman SJ; Bhatia S
JAMA Oncol; 2016 Oct; 2(10):1277-1286. PubMed ID: 27254472
[TBL] [Abstract][Full Text] [Related]
5. Longitudinal assessment of hematopoietic abnormalities after autologous hematopoietic cell transplantation for lymphoma.
Bhatia R; Van Heijzen K; Palmer A; Komiya A; Slovak ML; Chang KL; Fung H; Krishnan A; Molina A; Nademanee A; O'Donnell M; Popplewell L; Rodriguez R; Forman SJ; Bhatia S
J Clin Oncol; 2005 Sep; 23(27):6699-711. PubMed ID: 16170178
[TBL] [Abstract][Full Text] [Related]
6. Trends in use of and survival after autologous hematopoietic cell transplantation in North America, 1995-2005: significant improvement in survival for lymphoma and myeloma during a period of increasing recipient age.
McCarthy PL; Hahn T; Hassebroek A; Bredeson C; Gajewski J; Hale G; Isola L; Lazarus HM; Lee SJ; Lemaistre CF; Loberiza F; Maziarz RT; Rizzo JD; Joffe S; Parsons S; Majhail NS
Biol Blood Marrow Transplant; 2013 Jul; 19(7):1116-23. PubMed ID: 23660172
[TBL] [Abstract][Full Text] [Related]
7. Clonal Hematopoiesis and Cardiovascular Disease in Patients With Multiple Myeloma Undergoing Hematopoietic Cell Transplant.
Rhee JW; Pillai R; He T; Bosworth A; Chen S; Atencio L; Oganesyan A; Peng K; Guzman T; Lukas K; Sigala B; Iukuridze A; Lindenfeld L; Jamal F; Natarajan P; Goldsmith S; Krishnan A; Rosenzweig M; Wong FL; Forman SJ; Armenian S
JAMA Cardiol; 2024 Jan; 9(1):16-24. PubMed ID: 37938837
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of the Impact of Autologous Hematopoietic Stem Cell Transplantation on the Quality of Life of Older Patients with Lymphoma.
Lemieux C; Ahmad I; Bambace NM; Bernard L; Cohen S; Delisle JS; Fleury I; Kiss T; Mollica L; Roy DC; Sauvageau G; Roy J; Lachance S
Biol Blood Marrow Transplant; 2020 Jan; 26(1):157-161. PubMed ID: 31521818
[TBL] [Abstract][Full Text] [Related]
9. Engrafted Donor-Derived Clonal Hematopoiesis after Allogenic Hematopoietic Cell Transplantation is Associated with Chronic Graft-versus-Host Disease Requiring Immunosuppressive Therapy, but no Adverse Impact on Overall Survival or Relapse.
Newell LF; Williams T; Liu J; Yu Y; Chen Y; Booth GC; Knight RJ; Goslee KR; Cook RJ; Leonard J; Meyers G; Traer E; Press RD; Fan G; Wang Y; Raess PW; Maziarz RT; Dunlap J
Transplant Cell Ther; 2021 Aug; 27(8):662.e1-662.e9. PubMed ID: 33901720
[TBL] [Abstract][Full Text] [Related]
10. Comorbidities, Alcohol Use Disorder, and Age Predict Outcomes after Autologous Hematopoietic Cell Transplantation for Lymphoma.
Graf SA; Vaughn JE; Chauncey TR; Storer BE; Gopal AK; Holmberg LA; McCune JS; Bensinger WI; Maloney DG; Press OW; Storb R; Sorror ML
Biol Blood Marrow Transplant; 2016 Sep; 22(9):1582-1587. PubMed ID: 27311969
[TBL] [Abstract][Full Text] [Related]
11. Clonal Hematopoiesis Associated With Adverse Outcomes After Autologous Stem-Cell Transplantation for Lymphoma.
Gibson CJ; Lindsley RC; Tchekmedyian V; Mar BG; Shi J; Jaiswal S; Bosworth A; Francisco L; He J; Bansal A; Morgan EA; Lacasce AS; Freedman AS; Fisher DC; Jacobsen E; Armand P; Alyea EP; Koreth J; Ho V; Soiffer RJ; Antin JH; Ritz J; Nikiforow S; Forman SJ; Michor F; Neuberg D; Bhatia R; Bhatia S; Ebert BL
J Clin Oncol; 2017 May; 35(14):1598-1605. PubMed ID: 28068180
[TBL] [Abstract][Full Text] [Related]
12. Long-term outcomes among 2-year survivors of autologous hematopoietic cell transplantation for Hodgkin and diffuse large b-cell lymphoma.
Myers RM; Hill BT; Shaw BE; Kim S; Millard HR; Battiwalla M; Majhail NS; Buchbinder D; Lazarus HM; Savani BN; Flowers MED; D'Souza A; Ehrhardt MJ; Langston A; Yared JA; Hayashi RJ; Daly A; Olsson RF; Inamoto Y; Malone AK; DeFilipp Z; Margossian SP; Warwick AB; Jaglowski S; Beitinjaneh A; Fung H; Kasow KA; Marks DI; Reynolds J; Stockerl-Goldstein K; Wirk B; Wood WA; Hamadani M; Satwani P
Cancer; 2018 Feb; 124(4):816-825. PubMed ID: 29125192
[TBL] [Abstract][Full Text] [Related]
13. The Impact of Advanced Patient Age on Mortality after Allogeneic Hematopoietic Cell Transplantation for Non-Hodgkin Lymphoma: A Retrospective Study by the European Society for Blood and Marrow Transplantation Lymphoma Working Party.
Kyriakou C; Boumendil A; Finel H; Nn Norbert Schmitz ; Andersen NS; Blaise D; Chevallier P; Browne P; Malladi R; Niederwieser D; Pagliuca A; Kroschinsky F; Montoto S; Dreger P;
Biol Blood Marrow Transplant; 2019 Jan; 25(1):86-93. PubMed ID: 30219698
[TBL] [Abstract][Full Text] [Related]
14. Clinical significance of clonal hematopoiesis in the setting of autologous stem cell transplantation for lymphoma.
Lackraj T; Ben Barouch S; Medeiros JJF; Pedersen S; Danesh A; Bakhtiari M; Hong M; Tong K; Joynt J; Arruda A; Minden MD; Kuruvilla J; Bhella S; Kukreti V; Crump M; Prica A; Chen C; Deng Y; Xu W; Pugh TJ; Keating A; Dick JE; Abelson S; Kridel R
Am J Hematol; 2022 Dec; 97(12):1538-1547. PubMed ID: 36087071
[TBL] [Abstract][Full Text] [Related]
15. Hematopoietic Stem Cell Transplant Recipients Surviving at Least 2 Years from Transplant Have Survival Rates Approaching Population Levels in the Modern Era of Transplantation.
Kliman D; Nivison-Smith I; Gottlieb D; Hamad N; Kerridge I; Purtill D; Szer J; Ma D
Biol Blood Marrow Transplant; 2020 Sep; 26(9):1711-1718. PubMed ID: 32194285
[TBL] [Abstract][Full Text] [Related]
16. Factors associated with outcomes in allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning after failed myeloablative hematopoietic cell transplantation.
Baron F; Storb R; Storer BE; Maris MB; Niederwieser D; Shizuru JA; Chauncey TR; Bruno B; Forman SJ; McSweeney PA; Maziarz RT; Pulsipher MA; Agura ED; Wade J; Sorror M; Maloney DG; Sandmaier BM
J Clin Oncol; 2006 Sep; 24(25):4150-7. PubMed ID: 16896000
[TBL] [Abstract][Full Text] [Related]
17. Predicting Mortality after Autologous Transplant: Development of a Novel Risk Score.
Berro M; Chhabra S; Piñana JL; Arbelbide J; Rivas MM; Basquiera AL; Vitriu A; Requejo A; Milovic V; Yantorno S; Bentolila G; Garcia JJ; Castro M; Palmer S; Saslavsky M; Duarte P; Cerutti A; Jarchum G; Tisi Baña M; Thapa B; Solano C; Sureda A; Rovira M; Shaw BE; Kusminsky G;
Biol Blood Marrow Transplant; 2020 Oct; 26(10):1828-1832. PubMed ID: 32640312
[TBL] [Abstract][Full Text] [Related]
18. High-dose carmustine, etoposide, and cyclophosphamide followed by allogeneic hematopoietic cell transplantation for non-Hodgkin lymphoma.
Law LY; Horning SJ; Wong RM; Johnston LJ; Laport GG; Lowsky R; Shizuru JA; Blume KG; Negrin RS; Stockerl-Goldstein KE
Biol Blood Marrow Transplant; 2006 Jul; 12(7):703-11. PubMed ID: 16785059
[TBL] [Abstract][Full Text] [Related]
19. Myeloablative intravenous pharmacokinetically targeted busulfan plus fludarabine as conditioning for allogeneic hematopoietic cell transplantation in patients with non-Hodgkin lymphoma.
Ayala E; Figueroa J; Perkins J; Kim J; Yue B; Riches M; Nishihori T; Locke F; Anasetti C; Kharfan-Dabaja MA
Clin Lymphoma Myeloma Leuk; 2015 Jun; 15(6):335-40. PubMed ID: 25659459
[TBL] [Abstract][Full Text] [Related]
20. Impact of Pretransplantation (18)F-fluorodeoxy Glucose-Positron Emission Tomography Status on Outcomes after Allogeneic Hematopoietic Cell Transplantation for Non-Hodgkin Lymphoma.
Bachanova V; Burns LJ; Ahn KW; Laport GG; Akpek G; Kharfan-Dabaja MA; Nishihori T; Agura E; Armand P; Jaglowski SM; Cairo MS; Cashen AF; Cohen JB; D'Souza A; Freytes CO; Gale RP; Ganguly S; Ghosh N; Holmberg LA; Inwards DJ; Kanate AS; Lazarus HM; Malone AK; Munker R; Mussetti A; Norkin M; Prestidge TD; Rowe JM; Satwani P; Siddiqi T; Stiff PJ; William BM; Wirk B; Maloney DG; Smith SM; Sureda AM; Carreras J; Hamadani M;
Biol Blood Marrow Transplant; 2015 Sep; 21(9):1605-11. PubMed ID: 25983043
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
